当前位置：
X-MOL 学术
›
Int. J. Biol. Sci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Current advances in the development of SARS-CoV-2 vaccines
International Journal of Biological Sciences ( IF 9.2 ) Pub Date : 2021-1-1 , DOI: 10.7150/ijbs.52569 Annoor Awadasseid 1, 2 , Yanling Wu 3 , Yoshimasa Tanaka 4 , Wen Zhang 1
International Journal of Biological Sciences ( IF 9.2 ) Pub Date : 2021-1-1 , DOI: 10.7150/ijbs.52569 Annoor Awadasseid 1, 2 , Yanling Wu 3 , Yoshimasa Tanaka 4 , Wen Zhang 1
Affiliation
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc globally, which has put a heavy toll on public health, lives, and the world economy. Vaccination is considered as one of the greatest successes in medical history. Based on prior experience with the development of SARS-CoV vaccines, all COVID-19 vaccines must be subjected to the tests for protective effects and harmful risks derived from antibody-dependent enhancement that may contribute to augmented infectivity and/or eosinophilic infiltration. The SARS-CoV-2 vaccine is now being developed urgently in several different ways. China is regarded as one of the world's leading countries in SARS-CoV-2 vaccine development, up to date the last inactivated vaccine international clinical (Phase III) trial was launched in the United Arab Emirates by Sinopharm China National Biotec Group (CNBG). In this review, we outline the current status of vaccine development against clinically relevant SARS-CoV-2 strains, anticipating that such attempts would help create efficacious and sage SARS-CoV-2 vaccines.
更新日期：2021-01-01
京公网安备 11010802027423号